<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179748</url>
  </required_header>
  <id_info>
    <org_study_id>NN7008-4253</org_study_id>
    <secondary_id>U1111-1171-9845</secondary_id>
    <nct_id>NCT03179748</nct_id>
  </id_info>
  <brief_title>Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients</brief_title>
  <official_title>Non-interventional, Multi-Centre, Post-Authorisation Safety Study With Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is conducted in North America. The aim of the trial is to assess the safety of
      turoctocog alfa under conditions of routine clinical care in patients with haemophilia A in
      Mexico
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 20, 2018</start_date>
  <completion_date type="Anticipated">June 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse reactions</measure>
    <time_frame>3-36 months after enrollment</time_frame>
    <description>Count and % of events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>3-36 months after enrollment</time_frame>
    <description>Count and % of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in treatment of bleeds</measure>
    <time_frame>3-36 months after enrollment</time_frame>
    <description>Rated: Excellent, Good, Moderate or none</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of turoctocog alfa for prophylaxis</measure>
    <time_frame>3-36 months after enrollment</time_frame>
    <description>Measured in IU/kg/dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of turoctocog alfa for treatment of bleeds</measure>
    <time_frame>3-36 months after enrollment</time_frame>
    <description>Measured in IU/kg/bleeding episode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of turoctocog alfa for surgery and post-surgical period</measure>
    <time_frame>3-36 months after enrollment</time_frame>
    <description>Measured in IU/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with confirmed inhibitors</measure>
    <time_frame>3-36 months after enrollment</time_frame>
    <description>Count of presence of inhibitors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with allergic/hypersensitivity reactions to turoctocog alfa</measure>
    <time_frame>3-36 months after enrollment</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding episodes</measure>
    <time_frame>3-36 months after enrollment</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Haemophilia A</condition>
  <arm_group>
    <arm_group_label>turoctocog alfa</arm_group_label>
    <description>Patients with haemophilia A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>turoctocog alfa</intervention_name>
    <description>Patients will be treated with commercially available turoctocog alfa according to local clinical practice at the discretion of the physician</description>
    <arm_group_label>turoctocog alfa</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population are haemophilia A patients who based on the indication will benefit
        from treatment with turoctocog alfa. No limitation has been set to the severity of
        haemophilia A, gender, age, previously treated and untreated patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed consent obtained before any study-related activities (study-related activities
             are any procedure related to recording of data according to the protocol)

          -  Male and female patients with haemophilia A

          -  Age range is 0 years and above

          -  The decision to initiate treatment with commercially available turoctocog alfa has
             been made by the patient/Legally Acceptable Representative (LAR) and the treating
             physician before and independently from the decision to include the patient in this
             study

        Exclusion Criteria:

          -  Previous participation in this study. Participation is defined as having given
             informed consent in this study

          -  Known or suspected allergy to turoctocog alfa or related products

          -  Mental incapacity, unwillingness or language barriers precluding adequate
             understanding or cooperation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

